Alivus Life Sciences Q1FY27 PAT Grows 32% YoY to ₹1,601 Mn
Alivus Life Sciences Limited announced its financial results for the first quarter ended June 30, 2026 (Q1FY27). The company reported a revenue from operations of ₹6,404 Mn, a 6.4% year-over-year (YoY) growth, primarily driven by its non-GPL business which saw a 26.5% YoY increase. EBITDA for the quarter stood at ₹2,341 Mn, up 29.1% YoY, with margins at 36.6%. Profit After Tax (PAT) reached ₹1,601 Mn, marking a 31.8% YoY growth and achieving PAT margins of 25.0%. The company generated ₹901 Mn in free cash flow, ending the quarter with ₹8,802 Mn in cash and cash equivalents. Alivus Life Sciences reaffirmed its FY27 revenue growth guidance of 10%-12% and EBITDA margin target of 30%-32%. The company also provided updates on its capacity expansion projects in Solapur and the development of a new R&D facility in Taloja.
Key Highlights
- Q1FY27 PAT increased 31.8% YoY to ₹1,601 Mn, with margins at 25.0%.
- Revenue grew 6.4% YoY to ₹6,404 Mn, boosted by non-GPL business growth.
- EBITDA rose 29.1% YoY to ₹2,341 Mn, with margins reaching 36.6%.
- Company generated ₹901 Mn free cash flow and maintains a net debt-free status.
- FY27 revenue growth target of 10%-12% and EBITDA margins of 30%-32% reiterated.
Price Impact
More from GLS